文献速递妇产影像技术与安全

在8000余例无重大结构异常的妊娠中扩展性无创产前筛查与染色体微阵列分析的临床效用比较

Clinical utility of expanded non-invasive prenatal screening compared with chromosomal microarray analysis in over 8000 pregnancies without major structural anomaly.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

该回顾性队列研究基于8605例超声正常妊娠的CMA结果,计算5-NIPS及扩展NIPS的理论检出率。5-NIPS仅可检出36.1%的CMA显著发现,扩展常见微缺失和全基因组NIPS的附加价值分别为0.035%和0.14%,均远低于CMA的0.91%。

要点

  • 5-NIPS仅可检出36.1%的CMA临床显著发现,全基因组NIPS仍会漏检54.1%。
  • 扩展常见微缺失NIPS的附加价值约0.035%,全基因组NIPS约0.14%,均远低于CMA的0.91%。
  • 5-NIPS检出率在母血清筛查异常组为1.56%,软指标组为0.63%,高龄组为0.62%,<35岁组为0.15%。

核心结论

  • 5-NIPS甚至全基因组NIPS分别会漏检63.9%和54.1%的CMA临床显著发现,扩展NIPS的附加价值远低于CMA。

研究设计与样本

  • 回顾性队列研究,纳入2013年1月至2022年2月在Rabin医学中心遗传实验室数据库登记、超声正常(包括软指标和母血清筛查异常)并接受羊膜腔穿刺的8605例妊娠,以CMA结果为参考标准计算5-NIPS及扩展NIPS的理论检出率。

诊断标准与关键数值

  • 全队列8605例中CMA临床显著结果122例(1.4%),其中5-NIPS理论上可检出44例(36.1%)。
  • 5-NIPS检出率:母血清筛查异常642例中1.56%,软指标318例中0.63%,高龄(≥35岁)4378例中0.62%,<35岁3267例中0.15%。
  • 扩展常见微缺失NIPS额外检出3例(0.03%),全基因组NIPS(排除常见微缺失)额外检出9例(0.10%)。
  • 扩展NIPS相对于5-NIPS的附加价值在全队列及各亚组均显著低于CMA的附加价值(CMA附加价值0.91%)。

临床应用与阅片要点

  • 作者指出这些发现应有助于医疗从业者引导夫妇在产前侵入性检测与NIPS之间做出知情选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the theoretical added value of two types of non-invasive prenatal screening (NIPS) expansions in pregnancies without major structural anomalies over the commonly used NIPS for chromosomes 13, 18, 21, X and Y (5-NIPS) and to compare them with the added value of chromosomal microarray analysis (CMA).

METHODS: This was a retrospective cohort study based on CMA results of all pregnancies with normal ultrasound (including pregnancies with soft markers and with abnormal maternal serum screening) that had undergone amniocentesis between January 2013 to February 2022 and were registered in the database of the Rabin Medical Center genetic laboratory. We calculated the theoretical yield of 5-NIPS and compared the added value of expanded 5-NIPS for common microdeletions (1p36.3-1p36.2, 4p16.3-4p16.2, 5p15.3-5p15.1, 15q11.2-15q13.1 and 22q11.2) and genome-wide NIPS (including variants > 5 Mb) with the added value of CMA in the overall cohort and in subgroups according to indication for invasive testing.

RESULTS: Among the 8605 examined pregnancies, 122 (1.4%) clinically significant CMA results were demonstrated. Of these, 44 (36.1%) were theoretically detectable on 5-NIPS, with the rates of 1.56% in 642 pregnancies with abnormal maternal serum screening, 0.63% in 318 pregnancies with soft markers, 0.62% in 4378 women with advanced maternal age (≥ 35 years) and 0.15% in 3267 women younger than 35 years. In addition to aneuploidies detectable on 5-NIPS, three (0.03%) cases detectable on 5-NIPS expanded for common microdeletions and nine (0.10%) cases detectable on genome-wide NIPS (excluding common microdeletions) were identified in the overall cohort. The added value of expanded NIPS tools over 5-NIPS was significantly lower compared with that of CMA, for the overall cohort and subgroups.

CONCLUSIONS: 5-NIPS and even genome-wide NIPS would miss 63.9% and 54.1% of clinically significant CMA findings, respectively. The added value of 5-NIPS expanded to detect common microdeletions over 5-NIPS is about 0.035%, and the overall added value of genome-wide NIPS aimed at large CNVs is about 0.14%, both much lower compared with the added value of CMA (0.91%). These findings should assist healthcare practitioners in guiding couples towards informed decision-making regarding the choice between prenatal invasive testing and NIPS. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Maya I, Salzer Sheelo L, Brabbing-Goldstein D, et al. Clinical utility of expanded non-invasive prenatal screening compared with chromosomal microarray analysis in over 8000 pregnancies without major structural anomaly. Ultrasound Obstet Gynecol. 2023. PMID: 36776119. doi:10.1002/uog.26177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。